
ICLUSIG (ponatinib) offers convenient dosing in a single oral tablet1
Available in 45 mg, 30 mg, 15 mg, and 10 mg dosage strengths1
ICLUSIG is a single tablet taken orally once daily1
- Can be taken with or without food
- Tablets should be swallowed whole. Do not crush, break, cut, or chew tablets
- If a dose is missed, take the next dose at the regularly scheduled time the next day
ICLUSIG is available in multiple dosage strengths. Each dosage strength is available as a single oral tablet.1
Guidance for dose modification in CP-, AP-, BP-CML
ICLUSIG (ponatinib) dose modifications
Recommended Dose Modifications for ICLUSIG for Adverse Reactions1
Based on CTCAE v5.0: Grade 1 mild, Grade 2 moderate, Grade 3 severe, Grade 4 life-threatening
ICLUSIG (ponatinib) dose reductions
Recommended Dose Reductions for ICLUSIG for Adverse Reactions1
ICLUSIG (ponatinib) dosage with strong CYP3A inhibitors
Recommended ICLUSIG Dosage for Co-administration of Strong CYP3A Inhibitors1
ICLUSIG (ponatinib) dosage for patients with hepatic impairment1
Reduce the starting doses of ICLUSIG from 45 mg orally once daily to 30 mg orally once daily in patients with pre-existing hepatic impairment (Child-Pugh A, B, or C).
Dosing strategy in AP-CML, BP-CML, and Ph+ ALL1
- Optimal dose of ICLUSIG has not been identified in AP- and BP-CML
- Recommended starting dosage is 45 mg orally once daily
- Consider reducing dosage for patients with AP-CML who have achieved a major cytogenetic response
- Continue treatment with ICLUSIG until loss of response or unacceptable toxicity
- Consider discontinuing ICLUSIG if response has not occurred by 3 months
Learn about a response-based dosing approach with ICLUSIG
Discover which patients are appropriate for ICLUSIG
ALT=alanine transaminase; ANC=absolute neutrophil count; AOE=arterial occlusive events; AP-CML=accelerated-phase chronic myeloid leukemia; AST=aspartate aminotransferase; BCR-ABL1IS=BCR-ABL1 international scale; BP-CML=blast-phase chronic myeloid leukemia; CP-CML=chronic-phase chronic myeloid leukemia; CTCAE=Common Terminology Criteria for Adverse Events; TKI=tyrosine kinase inhibitor; ULN=upper limit of normal.